Contact this trialFirst, we need to learn more about you.
Janus Kinase (JAK) Inhibitor
Ruxolitinib Cream for Eczema
Recruiting1 awardPhase 3
Chicago, Illinois
This trial is testing whether ruxolitinib cream is an effective and safe treatment for children with Atopic Dermatitis. The trial is double-blind, meaning that neither the participants nor the researchers will know who is receiving the active treatment or the placebo until the trial is over. The trial is also stratified, meaning that the participants will be divided into groups based on their age and severity of Atopic Dermatitis.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.